article Open AccessTop 1% cited

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

Clinical Pharmacology & Therapeutics · 2006 · Vol. 80(1) · pp. 61–74

Sandra Regina de Oliveira Borges✉(Sidney Kimmel Comprehensive Cancer Center)Zereunesay Desta(Indiana University – Purdue University Indianapolis)L LI(Sidney Kimmel Comprehensive Cancer Center)Todd C. Skaar(University of Michigan–Ann Arbor)Brant R. Ward(Roche (Switzerland))Anne Nguyen(Indiana University School of Medicine)Yan Jin(Sidney Kimmel Comprehensive Cancer Center)A. M. Storniolo(Indiana University – Purdue University Indianapolis)D M Nikoloff(Indiana University School of Medicine)Lijun Wu(Johns Hopkins University)

View via DOI Publisher page

Abstract

CYP2D6 genotype and concomitant potent CYP2D6 inhibitors are highly associated with endoxifen plasma concentration and may have an impact on the response to tamoxifen therapy. These iterative approaches may be valuable in the study of other complex genotype-phenotype relationships.

Estrogen and related hormone effects Pharmacogenetics and Drug Metabolism Inflammatory mediators and NSAID effectsTamoxifenCYP2D6GenotypeBreast cancerPharmacologyActive metaboliteAllelePharmacogeneticsInternal medicineMedicine

MeSH terms

AdultAgedAged, 80 and overBreast NeoplasmsFemaleGenotypeHumansMiddle AgedPhenotypeProspective StudiesTamoxifenAntineoplastic Agents, HormonalCytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 Inhibitors